Published in Proteomics Weekly, April 24th, 2006
The data were presented at the Annual Meeting on Women's Cancer organized by the Society of Gynecologic Oncology.
The study is designed to test the ability of phenoxodiol to reverse the resistance that develops in most ovarian cancers to standard chemotherapy. The study was conducted at Yale-New Haven Hospital, Conn., U.S., and at the Royal Women's Hospital, Melbourne, Australia.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly